Overview of Philipon-S

Property	Description
Active ingredient	Meloxicam (INN)
Pharmacological class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
Sub-class	Oxicam derivative, Preferential COX-2 Inhibitor
Origin	Synthetic compound
Forms	Tablet, Capsule, Oral suspension, Solution for injection

What Type of Medicine is Philipon-S?

Philipon-S is a medicinal product defined by its single active component, Meloxicam, which is classified within the Nonsteroidal Anti-Inflammatory Drug (NSAID) class. This type of prescription medicine is widely recognized for its pain-relieving properties. Meloxicam is a chemically synthesized compound categorized as an oxicam derivative, distinguishing it structurally from other NSAID groups.

This classification is clinically recognized for favoring a specific therapeutic profile: Meloxicam is known for having a relatively long plasma half-life compared to other NSAIDs. This extended duration of action is a differentiating factor, allowing for sustained delivery of the active compound, which makes it a favorable option for those managing ongoing inflammatory symptoms.

Composition and Available Forms of Philipon-S

The therapeutic effect of Philipon-S is derived exclusively from the active ingredient Meloxicam, which is contained alongside pharmaceutically inert excipients necessary for the final preparation. Meloxicam is manufactured in several core pharmaceutical preparations to ensure flexibility in delivery.

These preparations commonly include various oral dosage forms, such as tablets, capsules, and oral suspensions, intended for oral ingestion. Importantly, the drug is also available as a solution for injection for parenteral (intravenous or intramuscular) administration. The availability of both oral and injectable forms allows healthcare professionals to optimize delivery based on the patient's immediate clinical needs.

What is the General Purpose of Philipon-S?

The general purpose of Philipon-S is to provide relief from the three primary symptoms associated with inflammatory processes: pain, inflammation, and fever. It achieves this by functioning as a preferential Cyclooxygenase-2 (COX-2) Inhibitor, a mechanism consistently noted in regulatory documents.

Meloxicam works by reducing the synthesis of prostaglandins, the chemical messengers responsible for initiating the inflammatory cascade. By preferentially inhibiting the COX-2 enzyme—the isoform primarily induced during inflammation—Philipon-S helps lessen tissue swelling and stiffness. This fundamental mechanism positions the medicine as a tool for symptomatic relief in conditions characterized by chronic inflammatory discomfort.

What side effects are possible with Philipon-S?

Possible Side Effects and Safety Information: Philipon-S

Philipon-S is a proprietary product, and its full safety profile is best understood in the context of its active ingredients. Consumers should be aware of potential adverse reactions associated with its constituents.

Reported side effects for compounds often found in similar formulations, based on clinical data and authoritative medical sources, generally fall into the following categories:

Gastrointestinal and Bleeding Risks

Common Reactions: Digestive system discomfort is frequent, which may include nausea, diarrhea, vomiting, and stomach upset or pain.
Serious Risks: A heightened risk of gastrointestinal ulcers and bleeding is possible, especially with prolonged use or in patients with pre-existing conditions. Unusual bleeding, such as black, tarry stools or blood in the urine, requires immediate medical attention.

Other Potential Adverse Effects

System	Possible Effects
Cardiovascular	Hypertension (high blood pressure) or effects on heart rate.
Dermatologic	Allergic skin reactions, rash, or increased sensitivity to sunlight (photosensitivity).
Ocular/Vision	Changes in vision, such as blurred vision or difficulty adjusting to light, have been reported and require ophthalmological evaluation.
Hematologic	Potential for thrombocytopenia (low platelet count), which increases the risk of bruising and bleeding.

Contraindications and Warnings

Philipon-S is typically contraindicated in patients with a known hypersensitivity to its components. Caution is advised for individuals with a history of or current stomach ulcers, significant bleeding or blood vessel problems (e.g., hemophilia), or severe renal or hepatic impairment. Due to the risk of increased bleeding, the drug may need to be withheld prior to surgical or dental procedures. Monitoring of liver enzymes is generally recommended during treatment.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Official regulatory information establishes that a Philipon-S (Meloxicam) overdose may present initially with gastrointestinal symptoms, including nausea, vomiting, and epigastric pain, alongside neurological effects such as drowsiness and lethargy. While many acute overdoses may be minor or asymptomatic, the documented risk exists for severe, life-threatening outcomes. These severe outcomes may affect the gastrointestinal system (bleeding, ulceration, and perforation), the renal system (acute renal failure, which is dose-dependent), and the cardiovascular system (collapse or cardiac arrest).

Required Emergency Actions

Due to the potential for severe toxicity, immediate medical attention must be sought for any suspected overdose. Contact emergency services immediately upon observing severe clinical signs, such as significant gastrointestinal bleeding or respiratory depression. Patients with pre-existing renal or hepatic impairment are noted to be at increased risk for severe toxicity and require specialized monitoring.

Management and Antidote Status

There is no specific antidote known for Meloxicam intoxication. Management is restricted to symptomatic and supportive treatment. Procedural measures described in regulatory labeling may include gastric lavage and the administration of activated charcoal to reduce absorption. The administration of Cholestyramine is also documented as a method to accelerate the elimination of Meloxicam from the body.

Therapeutic Uses of Philipon-S

What Philipon-S Treats: Main Uses and Benefits

Philipon-S is commonly used in clinical settings that involve chronic or disruptive symptom patterns stemming from underlying inflammatory joint diseases. It is applied in addressing conditions marked by increased discomfort or tension, specifically osteoarthritis (OA) and rheumatoid arthritis (RA) in adults. It is considered relevant for managing symptom clusters related to physical discomfort and inflammatory or irritative states, such as persistent joint pain, tenderness, and swelling.

The medication is commonly used to help with these manifestations, and its application supports the patient by easing the overall symptom load. It generally contributes to improved comfort during periods of heightened symptoms. Philipon-S is also relevant in situations where symptoms, particularly pronounced stiffness, create noticeable functional strain and interfere with daily functioning. By easing symptoms that interfere with daily comfort, the medication assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations. This supportive role is extended to conditions like Juvenile Idiopathic Arthritis (JIA) in pediatric patients (aged ge 2 years) and Ankylosing Spondylitis.

Quick Fact: Relief for Joint Discomfort Philipon-S is applied across domains where additional symptomatic support is needed for symptoms related to inflammatory or irritative states. It is commonly used to help with pain, swelling, and stiffness.

Regulatory References

NIH MedlinePlus overview of Meloxicam

Eligibility and Restrictions for Use

Philipon-S (meloxicam) is a nonsteroidal anti-inflammatory drug (NSAID) whose use is strictly governed by regulatory documentation regarding patient eligibility.

Contraindicated Populations (Must Not Use)

Use is prohibited for patients with a known hypersensitivity to meloxicam or a history of allergic-type reactions (such as asthma, hives, or rhinitis) after taking aspirin or other NSAIDs. The medicine is also contraindicated for the treatment of pain immediately before or after Coronary Artery Bypass Graft (CABG) surgery.

Age and Condition Restrictions

Pediatric Use: The medicine is generally approved for children 2 years of age and older. Safety and efficacy have not been established in children younger than two years. Older adults (ge 65 years) may be at greater risk for serious gastrointestinal or renal events.
Pregnancy: Philipon-S is contraindicated starting at 30 weeks gestation due to risk of harm to the fetus. Use is also generally advised to be avoided between 20 and 30 weeks gestation.
Organ Function: Use is not recommended in patients with severe renal impairment; avoidance is also advised for patients with severe heart failure or a recent myocardial infarction. Patients with severe hepatic impairment have not been adequately studied in clinical trials.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Philipon-S (Meloxicam) has documented interaction patterns that are classified based on official regulatory information, primarily affecting pharmacodynamic risk and pharmacokinetic clearance.

Co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including Aspirin at analgesic doses, is not generally recommended due to an officially documented increased risk of gastrointestinal (GI) bleeding and ulceration. The risk of bleeding is also stated to be increased when Philipon-S is combined with Anticoagulants (such as Warfarin), Antiplatelet agents, and Selective Serotonin Reuptake Inhibitors (SSRIs), reflecting an additive pharmacodynamic effect.

Regarding pharmacokinetic interactions, co-administration with strong inhibitors of the CYP2C9 enzyme may increase Meloxicam plasma concentrations. Furthermore, Philipon-S is officially documented to increase the plasma levels of both Lithium and Methotrexate when the latter is used at doses of 15 mg per week or higher, due to reduced clearance.

Interacting Class	Official Interaction Outcome
Diuretics / ACE Inhibitors / ARBs	Reduced antihypertensive effect; risk of renal function deterioration, especially in the elderly.
Ciclosporin (Cyclosporine)	Increased risk of nephrotoxicity.
Alcohol	Officially associated with an increased risk of gastrointestinal bleeding.

The official labeling notes that Antacids do not cause a clinically significant pharmacokinetic interaction. Population-specific cautions exist, stating that elderly patients and those with volume depletion are at heightened risk of renal function deterioration when using Philipon-S with blood pressure medicines.

Mechanism of Action

Targeting the Cyclooxygenase-2 (COX-2) Enzyme

Philipon-S's active ingredient, Meloxicam, functions as a preferential inhibitor of the Cyclooxygenase-2 (COX-2) enzyme, which catalyzes biochemical steps within the pathway that generates inflammatory mediators. This mechanism selectively targets the enzyme isoform that is typically induced during physiological responses, suppressing the catalytic turnover of Arachidonic Acid into Prostanoids.

Suppression of Prostaglandin Synthesis

The enzyme blockade directly interrupts the Prostaglandin Synthesis Pathway, drastically decreasing the local concentration of lipid mediators, such as Prostaglandin E2 (PGE2). This reduction modifies early molecular steps that shape systemic physiological outcomes, which subsequently modulates the prostanoid-mediated effects on local vascular permeability.

Modulation of Nociceptor Sensitization and Thermoregulation

By suppressing PGE2 levels, the mechanism leads to a dual physiological consequence: it reduces the Prostaglandin-mediated sensitization of peripheral nociceptors, thereby regulating the initiation of sensory signals; and it modulates the central hypothalamic mechanism responsible for controlling the core temperature set-point.

Dosage and Administration Information

Administration Overview

Philipon-S is designed for oral administration. Consistency in how the medication is taken is a primary factor in maintaining stable levels of the active components within the body.

Timing and Routine

Establishing a regular schedule helps ensure the medication is integrated into a daily routine. Most individuals find that taking the dose at the same time each day assists with adherence.

Factors Influencing Absorption

The presence of food in the digestive tract can influence how Philipon-S is processed. Some individuals may be advised to take the medication with a meal to manage gastrointestinal comfort, while others may be advised to take it on an empty stomach to facilitate faster absorption. It is important to maintain a consistent approach to food intake relative to the timing of the dose.

Handling and Storage

Proper maintenance of the medication ensures its integrity. Philipon-S should be kept in its original packaging until the time of use to protect it from environmental factors such as light and moisture. The storage area should be kept at a stable room temperature, away from excessive heat or humidity, such as that found in bathrooms or near kitchen appliances.

Recent Clinical Evidence

Philipon-S: Recent Clinical Evidence

Clinical development for Philipon-S has primarily focused on its investigation for inflammatory conditions, progressing through Phase I, II, and III trials to evaluate its tolerability and observations on disease activity.

Phase I and II: Initial Tolerability and Dose Exploration

Initial Phase I trials investigated the drug's first-in-human tolerability and pharmacokinetics (how the body handles the drug). These studies explored a potential mechanism involving the inhibition of a specific inflammatory pathway.

Phase II studies evaluated various dose ranges. Evidence remains limited regarding the optimal dose to maximize a potential clinical finding while maintaining a suitable tolerability profile. The trials investigated a possible change on biomarkers associated with inflammation.

Phase III: Pivotal Trial Findings

Large-scale Phase III studies were conducted globally to evaluate the drug against established comparators or placebo. Findings explored the drug's profile related to core disease symptoms and long-term outcomes.

Symptom Investigation

Research has evaluated whether joint mobility may be affected and investigated observations on pain scales. One study reported a mean change in a pain scale of 40%. A separate large-scale trial reported an observation on preventing disease progression.

Long-Term and Combination Data

Long-term extension studies examined whether changes in flare-up frequency were maintained over time. Comparative studies examined potential differences between this approach and older treatments, as well as when used in combination with other therapies.

Studies have investigated the drug's tolerability in elderly patients.
Clinical data explored the tolerability and pharmacokinetics of a lower starting dose for individuals with severe kidney impairment.

Research efforts continue to examine the drug's long-term profile.

Frequently Asked Questions (FAQ)

Common questions about Philipon-S (FAQ)

Q: What is the main difference between Philipon-S and other similar medicines I've heard of?

A: Philipon-S is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID).

Regulatory documents state that its relatively long elimination half-life, which can range from 15 to 20 hours, is a factor that distinguishes it from many other NSAIDs. This extended half-life supports its typical once-daily use regimen.

Q: Can I take Philipon-S if I'm trying to become pregnant?

A: Official regulatory guidance concerning NSAIDs generally advises against their use in women who are actively attempting to conceive or undergoing fertility treatments.

This is because nonsteroidal anti-inflammatory drugs like Philipon-S may be associated with reversible effects on ovulation.

Q: Are there any specific foods or drinks that should be avoided with Philipon-S?

A: According to the official product information, Philipon-S can typically be taken without regard to the timing of meals.

However, the labeling explicitly associates the consumption of alcohol with an increased risk of serious gastrointestinal bleeding.

Q: How long does Philipon-S stay in your system after the last use?

A: The average elimination half-life of Philipon-S is reported to be between 15 and 20 hours.

For a medicine to be considered largely cleared from the body, it generally takes approximately four to five of these half-lives.

Q: What are the most common reasons a doctor might prescribe Philipon-S?

A: Philipon-S is officially indicated for the management and relief of the signs and symptoms of several chronic inflammatory conditions.

These approved indications include osteoarthritis, rheumatoid arthritis, and juvenile idiopathic arthritis in patients aged 2 years and older.

Q: Are there different versions or brands of Philipon-S available?

A: Philipon-S is the proprietary brand name for the active ingredient meloxicam.

Meloxicam is available as a generic medicine in various forms, in addition to the proprietary product.

Q: What are the long-term effects described in research for Philipon-S?

A: Official warnings for NSAIDs, including Philipon-S, caution that an increased risk of serious cardiovascular thrombotic events, such as heart attack and stroke, may occur.

There is also a heightened risk of serious gastrointestinal side effects, including bleeding and ulceration, which may be increased with higher dosage and longer duration of use.

Q: What kind of monitoring is typically done when a person is on Philipon-S?

A: Regulatory labeling indicates that monitoring of liver enzymes may be appropriate during treatment.

Warnings also describe that monitoring of blood pressure and renal (kidney) function may be carried out for patients at risk of kidney toxicity or hypertension.

Q: Is Philipon-S effective for preventing a condition, or only for treating it?

A: Philipon-S is approved for the symptomatic relief of pain and inflammation, classifying its official role as treatment for existing symptoms.

However, clinical studies have also examined its potential effects regarding the prevention of disease progression in certain chronic inflammatory conditions.

Q: What are the common signs that Philipon-S is starting to work?

A: As Philipon-S is intended to relieve pain and inflammation, the drug’s intended effect is related to a decrease in these symptoms.

Studies investigate changes in functional measures, such as improvements in joint mobility and measurable decreases in pain levels.

Q: Is the list of side effects in the official documents exhaustive?

A: The list of side effects provided in regulatory documents summarizes the most frequent or serious adverse reactions observed in clinical trials and during post-marketing surveillance.

Official information indicates this list is not considered exhaustive, and other effects may be possible.

Q: Is Philipon-S considered a new or older medicine?

A: Philipon-S is a chemically synthesized NSAID that is structurally categorized as an oxicam derivative.

Research evidence indicates that its profile is examined in comparison with older treatments in its class.

Q: What official documents describe the recommended duration of use for Philipon-S?

A: The guidance on the recommended duration of use is defined in the official prescribing information, such as the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).

These documents mandate utilizing the lowest effective dose for the shortest possible duration.

Q: Can Philipon-S be used in conjunction with physical therapy or other non-drug treatments?

A: Clinical trials have examined the use of Philipon-S in combination with other therapies.

This evidence suggests the medicine is positioned to be part of a comprehensive treatment plan, which may include non-drug approaches like physical therapy.

Q: Does Philipon-S show up on standard drug tests?

A: Philipon-S is generally not included in routine drug screening panels.

However, official toxicological information indicates that the active ingredient can be detected if specifically tested for, potentially remaining in urine for several days after administration.

Q: How long does it typically take to feel the effects of Philipon-S?

A: Following oral administration, the active ingredient in Philipon-S typically reaches its peak concentration in the blood within 4 to 5 hours.

The precise time it takes to feel symptomatic pain relief can vary between individuals.

Q: Are the side effects of Philipon-S permanent?

A: While most reported side effects are temporary and reversible upon stopping the medication, serious adverse effects are possible.

The official warnings indicate that serious events, such as gastrointestinal bleeding or cardiovascular issues, can result in permanent harm or be fatal.

Q: Does Philipon-S interact with common supplements like vitamins or herbal remedies?

A: Official regulatory information generally does not provide specific interaction details for every common vitamin or herbal remedy.

However, official warnings cover interactions with many agents that affect bleeding risk or liver enzyme function.

Q: Why is Philipon-S described as a 'scheduled' drug or controlled substance?

A: Philipon-S is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is not scheduled as a controlled substance.

This means it is not regulated under frameworks such as the US Controlled Substances Act (CSA).

Q: Can Philipon-S cause changes in my mood or behavior?

A: Official reporting does not list severe mood or behavioral changes as common adverse reactions.

However, central nervous system (CNS) effects, including dizziness, nervousness, and somnolence (drowsiness), have been reported in clinical trials.

Q: What is the risk of dependence or addiction with Philipon-S?

A: Philipon-S is not an opioid and is not a controlled substance.

Therefore, the risk for physical dependence or addiction associated with its use is described as very low.

Q: What happens if I stop taking Philipon-S suddenly?

A: Philipon-S is generally not associated with physical withdrawal symptoms upon sudden cessation.

However, discontinuing use for chronic inflammatory conditions may result in a return or 'rebound' of symptoms like pain, inflammation, and stiffness.

Q: Is it common to feel tired or drowsy when first starting Philipon-S?

A: Somnolence (drowsiness) is listed among the adverse reactions reported in regulatory documents.

Dizziness is also listed as a potential side effect related to the nervous system.

Q: Can Philipon-S affect my ability to drive or operate machinery?

A: Regulatory documents state that dizziness, drowsiness, or changes in vision have been reported with this drug.

The potential for these disturbances should be considered before engaging in the safe operation of a vehicle or machinery.

Q: Can men use Philipon-S if they plan on fathering a child?

A: Official labeling indicates that NSAIDs may be associated with reversible delays in female ovulation.

There are currently no specific warnings consistently documented in official sections related to male reproductive potential when planning to father a child.

Q: Do I need to change the way I use Philipon-S if I travel to a different time zone?

A: Philipon-S is a once-daily medicine with a long half-life.

Official dosing instructions support the continuation of the once-daily administration schedule, generally seeking to keep the time of day relatively consistent, even when traveling.

Q: Are there any genetic factors that affect how well Philipon-S works for someone?

A: Philipon-S is primarily metabolized by the CYP2C9 enzyme, according to official pharmacokinetic data.

Genetic differences, known as polymorphisms, in the activity of this enzyme may consequently affect the rate at which the drug is cleared from the body.

Q: If I miss a planned use of Philipon-S, what does the official guidance say?

A: Official patient information generally provides guidance for a missed use.

Guidance on a missed use is generally provided in the patient information leaflet, which outlines steps to follow, such as skipping a dose if it is close to the next scheduled time.

Q: Has Philipon-S been approved in countries outside the US?

A: Yes, Philipon-S (Meloxicam) has been authorized for use by regulatory bodies outside the United States.

This includes approval from agencies such as the European Medicines Agency (EMA) and Health Canada.

Q: Why is Philipon-S only available with a prescription?

A: Philipon-S is classified as a prescription-only medicine (Rx).

This classification is due to its association with potential serious risks, including cardiovascular and gastrointestinal events, which require ongoing professional medical supervision and monitoring.

Q: How is the safety of Philipon-S monitored after it has been approved?

A: The safety profile of the drug is continuously monitored after its approval and release to the market.

This monitoring is carried out through global pharmacovigilance programs that collect and analyze adverse event reports from healthcare professionals and the public.

Q: Does Philipon-S cause weight gain or loss?

A: Fluid retention, or edema, is a reported adverse reaction associated with this medicine.

In addition to fluid retention, weight gain or weight loss have also been reported in clinical trials in rare instances.

Q: Is Philipon-S safe to use while breastfeeding?

A: The official risk summary indicates that there is insufficient data available on the presence of Philipon-S in human milk.

Likewise, there is a lack of sufficient data on potential effects on the breastfed infant or any effects on milk production.

How should Philipon-S be stored and disposed of?

Storage Conditions

Official regulatory labeling dictates that Philipon-S must be stored at a temperature below 25°C. The medicine should be kept in its original package to ensure protection from both light and moisture. The solution for injection form must be protected from freezing. For the oral suspension, the container should be kept tightly closed, and any unused portion must be discarded 30 days after the first opening.

Child Safety and Disposal

It is a mandatory requirement to keep Philipon-S out of the sight and reach of children. Unused or expired medicine must be handled and disposed of in accordance with local regulatory requirements for pharmaceutical waste. The product should not be disposed of via household wastewater or domestic trash to prevent environmental contamination.

Philipon-S